Seroatlas · Human Serome Atlas

GPR19

Probable G-protein coupled receptor 19

Also known as: GPR19_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q15760
Gene: GPR19
Ensembl: ENSG00000183150
Chromosome: 12
Canonical length: 415 aa
Protein class: G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins

OverviewNCBI Gene

Predicted to enable G protein-coupled receptor activity. Predicted to be involved in G protein-coupled receptor signaling pathway. Located in cilium. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

415 residues, UniProt reviewed canonical sequence.

>Q15760|GPR19
     1  MVFAHRMDNS KPHLIIPTLL VPLQNRSCTE TATPLPSQYL MELSEEHSWM SNQTDLHYVL
    61  KPGEVATASI FFGILWLFSI FGNSLVCLVI HRSRRTQSTT NYFVVSMACA DLLISVASTP
   121  FVLLQFTTGR WTLGSATCKV VRYFQYLTPG VQIYVLLSIC IDRFYTIVYP LSFKVSREKA
   181  KKMIAASWVF DAGFVTPVLF FYGSNWDSHC NYFLPSSWEG TAYTVIHFLV GFVIPSVLII
   241  LFYQKVIKYI WRIGTDGRTV RRTMNIVPRT KVKTIKMFLI LNLLFLLSWL PFHVAQLWHP
   301  HEQDYKKSSL VFTAITWISF SSSASKPTLY SIYNANFRRG MKETFCMSSM KCYRSNAYTI
   361  TTSSRMAKKN YVGISEIPSM AKTITKDSIY DSFDREAKEK KLAWPINSNP PNTFV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GPR19 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0.4
Highest tissue expression: 7.8 nTPM

Expression across tissuesHPA

Tissue

cerebellum: 7.8 nTPM
pituitary gland: 7.4 nTPM
basal ganglia: 6.9 nTPM
hypothalamus: 6.8 nTPM
spinal cord: 5.8 nTPM
amygdala: 5.1 nTPM

Single-cell type

early primary spermatocytes: 29 nCPM
somatotrophs: 26 nCPM
lactotrophs: 26 nCPM
brain excitatory neurons: 21 nCPM
brain inhibitory neurons: 21 nCPM
oligodendrocyte progenitor cells: 20 nCPM

Immune cell

T-reg: 6.4 nTPM
neutrophil: 2.9 nTPM
memory CD4 T-cell: 2.4 nTPM
memory CD8 T-cell: 1.4 nTPM
gdT-cell: 1.2 nTPM
naive CD8 T-cell: 0.9 nTPM

Brain region

hypothalamus: 13 nTPM
cerebellum: 13 nTPM
cerebral cortex: 8.8 nTPM
basal ganglia: 8.6 nTPM
thalamus: 8.6 nTPM
spinal cord: 8.3 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.68
gnomAD pLI: 0.1
gnomAD missense Z: 1.45
DepMap mean gene effect: -0.02
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

G protein-coupled receptor signaling pathway

Molecular functions

G protein-coupled receptor activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

G protein-coupled receptor, rhodopsin-like
GPCR, rhodopsin-like, 7TM
7 transmembrane receptor (rhodopsin family)
G protein-coupled receptor 19, 7TM

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GPR19 as an antibody target. Whether an autoantibody or antibody against GPR19 could matter depends on whether native GPR19 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GPR19 is annotated at the cell surface, where native GPR19 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label GPR19 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...